VIVUS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2014-11-26: Form 8-K; Period of report 2014-11-26; Description 8.01 Other Events; Details 8.01.
- 2014-11-12: Form 8-K; Period of report 2014-11-05; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2014-11-05: Form 8-K; Period of report 2014-11-05; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2014-09-18: Form 8-K; Period of report 2014-09-17; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2014-11-26 | 8-K | 2014-11-26 | 8.01 Other Events | 8.01 On November 26, 2014, VIVUS, Inc., or VIVUS, issued a press release titled “VIVUS Announces Issuance of Two Additional U.S. Patents for Qsymia.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. | a14-25192_18k.htm |
| 2014-11-12 | 8-K | 2014-11-05 | 2.02 Results of Operations and Financial Condition | 2.02 On November 5, 2014, VIVUS, Inc., or the Company, conducted a conference call during which members of its senior management team discussed financial results for the third quarter and nine months ended September 30, 2014, a business update and certain other information. | a14-24175_18k.htm |
| 2014-11-05 | 8-K | 2014-11-05 | 2.02 Results of Operations and Financial Condition | 2.02 On November 5, 2014, VIVUS, Inc., or the Company, issued a press release regarding its financial results for the third quarter and nine months ended September 30, 2014, a business update and certain other information. | a14-23508_18k.htm |
| 2014-09-18 | 8-K | 2014-09-17 | 8.01 Other Events | 8.01 On September 18, 2014, VIVUS, Inc. issued a press release titled “VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to be Taken Approximately 15 Minutes Before Sexual Activity.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. | a14-19960_38k.htm |
| 2014-09-16 | 8-K | 2014-09-12 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On September 12, 2014, VIVUS, Inc., or the Company, held its 2014 Annual Meeting of Stockholders, or the Annual Meeting. | a14-21017_18k.htm |
| 2014-08-28 | 8-K | 2014-08-24 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a14-19960_28k.htm |
| 2014-08-25 | 8-K | 2014-08-22 | 8.01 Other Events | 8.01 On August 25, 2014, VIVUS, Inc. issued a press release titled “VIVUS Announces Acquisition of Topiramate-Related Patents from Janssen Pharmaceuticals.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. | a14-19960_18k.htm |
| 2014-08-15 | 8-K | 2014-08-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On August 12, 2014, Michael J. Astrue notified VIVUS, Inc., or the Company, that he will not stand for re-election to the Company’s Board of Directors at the next annual meeting of stockholders. | a14-19082_18k.htm |
| 2014-08-12 | 8-K | 2014-08-07 | 1.01 Entry into a Material Definitive Agreement | 1.01 On August 7, 2014, the Board of Directors of VIVUS, Inc., or the Company, approved a new form of Indemnification Agreement to be entered into with the Company’s directors, which will supersede and replace any prior Indemnification Agreements entered into with the Company’s directors. | a14-18862_18k.htm |
| 2014-08-12 | 8-K | 2014-08-07 | 2.02 Results of Operations and Financial Condition | 2.02 On August 7, 2014, VIVUS, Inc., or the Company, conducted a conference call during which members of its senior management team discussed financial results for the second quarter ended June 30, 2014, a business update and certain other information. | a14-18862_28k.htm |
| 2014-08-07 | 8-K | 2014-08-07 | 2.02 Results of Operations and Financial Condition | 2.02 On August 7, 2014, VIVUS, Inc., or the Company, issued a press release regarding its financial results for the second quarter ended June 30, 2014, a business update and certain other information. | a14-18394_18k.htm |
| 2014-06-17 | 8-K/A | 2014-06-17 | 7.01 Regulation FD Disclosure | 7.01 In connection with the attendance of the Company at the 2014 Wells Fargo Healthcare Conference, the Company distributed and presented the slide attached hereto as Exhibit 99.1 as part of the Presentation that was filed as Exhibit 99.1 to the Company’s Original Filing. | a14-15606_18ka.htm |
| 2014-06-17 | 8-K | 2014-06-17 | 7.01 Regulation FD Disclosure | 7.01 In connection with the attendance of VIVUS, Inc., or the Company, at the 2014 Wells Fargo Healthcare Conference, the Company will be distributing and presenting the slides attached hereto as Exhibit 99.1; such slides are incorporated by reference herein. | a14-15551_18k.htm |
| 2014-06-13 | 8-K | 2014-06-09 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On June 10, 2014, Robert N. Wilson notified VIVUS, Inc., or the Company, of his decision to resign from the Company’s Board of Directors, or the Board, effective June 20, 2014. | a14-15303_18k.htm |
| 2014-06-12 | 8-K | 2014-06-12 | 8.01 Other Events | 8.01 On June 12, 2014, VIVUS, Inc. issued a press release titled “VIVUS Files Lawsuit Against Actavis for Infringement of Qsymia Patents.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. | a14-15285_18k.htm |
| 2014-05-09 | 8-K | 2014-05-05 | 2.02 Results of Operations and Financial Condition | 2.02 On May 5, 2014, VIVUS, Inc., or the Company, conducted a conference call during which members of its senior management team discussed financial results for the first quarter ended March 31, 2014, a business update and certain other information. | a14-12375_18k.htm |
| 2014-05-09 | 8-K | 2014-05-07 | 8.01 Other Events | 8.01 On May 7, 2014, VIVUS, Inc., or the Company, received notice from Actavis Laboratories FL, Inc., or Actavis, that it has filed with the U.S. Food and Drug Administration, or the FDA, an Abbreviated New Drug Application , or ANDA, for generic versions of all strengths of Qsymia® (phentermine and topiramate extended release) capsules CIV. | a14-12375_28k.htm |
| 2014-05-05 | 8-K | 2014-05-05 | 2.02 Results of Operations and Financial Condition | 2.02 On May 5, 2014, VIVUS, Inc., or the Company, issued a press release regarding its financial results for the first quarter ended March 31, 2014, a business update and certain other information. | a14-11901_18k.htm |
| 2014-04-08 | 8-K | 2014-04-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On April 2, 2014, J. Martin Carroll and Robert N. Wilson notified VIVUS, Inc., or the Company, that they will not stand for re-election to the Company’s Board of Directors, or the Board, at the next annual meeting of stockholders. | a14-10079_18k.htm |
| 2014-04-08 | 8-K | 2014-04-08 | 7.01 Regulation FD Disclosure | 7.01 In connection with the attendance of VIVUS, Inc., or the Company, at the 13th Annual Needham Healthcare Conference, the Company will be distributing and presenting the slides attached hereto as Exhibit 99.1; such slides are incorporated by reference herein. | a14-10079_28k.htm |
| 2014-02-28 | 8-K | 2014-02-24 | 2.02 Results of Operations and Financial Condition | 2.02 On February 24, 2014, VIVUS, Inc., or the Company, conducted a conference call during which members of its senior management team discussed financial results for the fourth quarter and year ended December 31, 2013, a business update and certain other information. | a14-6933_18k.htm |
| 2014-02-24 | 8-K | 2014-02-24 | 2.02 Results of Operations and Financial Condition | 2.02 On February 24, 2014, VIVUS, Inc., or the Company, issued a press release regarding its financial results for the fourth quarter and year ended December 31, 2013, a business update and certain other information. | a14-6562_18k.htm |
| 2014-01-30 | 8-K | 2014-01-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 28, 2014, the Compensation Committee of the Board of Directors, or the Compensation Committee, of VIVUS, Inc., or the Company, authorized and approved cash bonus payments pursuant to the Company’s employee annual bonus plan for fiscal year 2013 adopted on the same date, or the Annual Bonus Plan, and stock option awards and restricted stock unit awards under the Company’s 2010 Equity Incentive Plan to certain of the Company’s employees, including executive officers Seth H. Z. Fischer, Chief Executive Officer, Svai S. Sanford, interim Chief Financial Officer, Principal Accounting Officer, Guy P. Marsh, Vice President, U.S. Operations and General Manager, Wesley W. Day, Ph.D., Vice President, Clinical Development and John L. Slebir, Senior Vice President, Business Development and General Counsel and Secretary. | a14-4692_18k.htm |
| 2014-01-24 | 8-K | 2014-01-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 22, 2014, the Compensation Committee of the Board of Directors of VIVUS, Inc., or the Company, authorized and approved the grant of restricted stock unit awards under the Company’s 2010 Equity Incentive Plan to certain of the Company’s employees including Svai Sanford, the Company’s interim Chief Financial Officer, Principal Accounting Officer, Guy P. Marsh, the Company’s Vice President, U.S. Operations and General Manager, Wesley W. Day, Ph.D., the Company’s Vice President, Clinical Development, and John L. Slebir, the Company’s Vice President, Business Development and General Counsel. | a14-4276_18k.htm |
| 2014-01-17 | 8-K | 2014-01-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 16, 2014, Seth H. Z. Fischer, the Chief Executive Officer of VIVUS, Inc., or the Company, assumed the duties and responsibilities of the Chief Commercial Officer of the Company. | a14-3818_18k.htm |
| 2014-01-14 | 8-K | 2014-01-14 | 7.01 Regulation FD Disclosure | 7.01 In connection with the attendance of VIVUS, Inc., or the Company, at the 32nd Annual J.P. Morgan Healthcare Conference to be held at the Westin St. Francis Hotel in San Francisco, California, the Company will be presenting an overview of the Company on January 15, 2014 at 3:30 pm PST. | a14-3517_18k.htm |
| 2014-01-02 | 8-K | 2013-12-30 | 8.01 Other Events | 8.01 On December 30, 2013, VIVUS, Inc. entered into a Rebate Agreement with CaremarkPCS Health, L.L.C., or Caremark, a pharmacy benefit manager. | a13-27271_18k.htm |